Long-term administration of angiotensin (1⿿7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes ( db/db ) by reducing oxidative stress, inflammation and pathological remodeling-Reference-Cited by-同舟云学术

Long-term administration of angiotensin (1⿿7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes ( db/db ) by reducing oxidative stress, inflammation and pathological remodeling

Published:2016-05 Issue: Volume:107 Page:372-380
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Papinska Anna M.,Soto Maira,Meeks Christopher J.,Rodgers Kathleen E.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Pharmacology

Reference41 articles.

1. Role of angiotensin and oxidative stress in essential hypertension;Romero;Hypertension,1999

2. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system;Zimmerman;Circ. Res.,2004

3. NF- κB inhibition ameliorates angiotensin II-Induced inflammatory damage in rats;Muller;Hypertension,2000

4. Inflammation and angiotensin II;Suzuki;Int. J. Biochem. Cell Ciol.,2003

5. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression AJP⿿regulatory;Chabrashvili;Integr. Comp. Physiol.,2003

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin 1–7 increases cardiac tolerance to ischemia/reperfusion and mitigates adverse remodeling of the heart—The signaling mechanism;Fundamental & Clinical Pharmacology;2024-02-04

2. Diabetic Pneumopathy- A Novel Diabetes-associated Complication: Pathophysiology, the Underlying Mechanism and Combination Medication;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-10-10

3. PDZK1 improves ventricular remodeling in hypertensive rats by regulating the stability of the Mas receptor;Amino Acids;2023-09-11

4. The therapeutic potential of angiotensin-(1–7);Angiotensin;2023

5. Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?;Frontiers in Drug Discovery;2022-08-11